Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma

Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial

This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment.

Biopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety.

The primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Typ studie

Intervenční

Zápis (Odhadovaný)

3300

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Zhejiang
      • Hangzhou, Zhejiang, Čína, 311200
        • The Second Affiliated Hospital of Zhejiang University School of Medicine
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  1. Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma);
  2. Candidate for limb-sparing surgery and capable of en-bloc resection;
  3. Age ≥ 5 years;
  4. ECOG performance status 0-2;
  5. Able to understand and sign informed consent.

Exclusion Criteria:

  1. Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions;
  2. Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery;
  3. Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis;
  4. Patients requiring amputation;
  5. Patients who have received prior treatment for the tumor at non-participating centers;
  6. Patients with an expected survival of less than 2 years;
  7. Patients in whom the biopsy tract completely lies within the planned tumor resection field;
  8. Patients who refuse to provide written informed consent.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: tract resection group

Surgeons will perform standard en-bloc tumor resection according to oncologic principles. In the biopsy tract resection group, complete biopsy tract excision is defined as en-bloc removal of the entire needle biopsy pathway, including:

Skin entry site: the original puncture site on the skin surface Subcutaneous and soft tissue tract: all intervening tissues traversed by the biopsy needle Deep tract structures: any muscle, fascia, periosteum, or bone structures penetrated by the needle Intratumoral component: the terminal segment of the needle pathway within the tumor

All components of the biopsy tract must be removed together with the tumor specimen.

Aktivní komparátor: tract non-section group

Surgeons will perform standard en bloc tumor resection in accordance with oncologic principles. In the non-resection group, the needle biopsy tract will not be intentionally excised. The biopsy tract, including the skin entry site and intervening soft tissue pathway, will be preserved unless it lies within the planned tumor resection field.

If any portion of the biopsy tract is located within the standard oncologic resection field required to achieve negative margins, it will be removed as part of the tumor specimen; however, no additional resection will be performed specifically to excise the biopsy tract.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Cumulative incidence of local recurrence at 2 years
Časové okno: From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.
Local recurrence is defined as radiologically or pathologically confirmed recurrence of sarcoma at or adjacent to the primary surgical site after definitive tumor resection. The cumulative incidence of local recurrence will be estimated with death treated as a competing event.
From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Musculoskeletal Tumor Society score
Časové okno: recorded at baseline and at 3, 6, 9, 12, 15, 18, 21, and 24 months after surgery.
MSTS assesses 6 aspects of a patient's quality including pain, function, emotional, supports, walking and gait with regard to their treatment. higher score. The score ranges from 0% (worst function) to 100% (best function). It is a repeated continuous outcome.
recorded at baseline and at 3, 6, 9, 12, 15, 18, 21, and 24 months after surgery.
Henderson failure mode
Časové okno: From surgery to 24 months, assessed every 3 months
Henderson failure mode defined as : soft-tissue failure (Type 1), aseptic loosening (Type 2), structural failure (Type 3), infection (Type 4), and tumor progression (Type 5).
From surgery to 24 months, assessed every 3 months
The Patient and Observer Scar Assessment Scale
Časové okno: From surgery to 24 months, assessed every 3 months
The Patient and Observer Scar Assessment Scale (POSAS) questionnare is used to evaluate scar quality from both the patient's and the observer's perspectives. Each scale consists of six items, with each item scored from 1 (normal skin) to 10 (worst imaginable scar). Total scores range from 6 to 60, with lower scores indicating better quality.
From surgery to 24 months, assessed every 3 months
Soft tissue reconstruction
Časové okno: perioperative period
Soft tissue reconstruction will be recorded as whether the patient required additional soft tissue reconstruction procedures (e.g., skin grafting) during surgery.
perioperative period
Total surgical duration
Časové okno: During the operative procedure
The time elapsed from the first incision to the completion of wound closure, measured in minutes.
During the operative procedure
Biopsy diagnostic accuracy
Časové okno: perioperative period
Diagnostic accuracy was defined as the percentage of participants whose percutaneous biopsy results are concordant with the final histopathological diagnosis from the surgical specimen. This is a binary outcome.
perioperative period
Metastasis free survival (MFS)
Časové okno: From surgery to 24 months, assessed every 6 months
Metastasis-free survival is defined as the time from definitive surgery to the first radiologically confirmed distant metastasis (e.g., lung, bone, or other organs). Metastasis will be assessed using scheduled chest CT scans and other imaging as clinically indicated. Participants without metastasis will be censored at their last follow-up visit.
From surgery to 24 months, assessed every 6 months
The Toronto Extremity Salvage Score
Časové okno: From surgery to 24 months, assessed every 3 months
The Toronto Extremity Salvage Score (TESS) is a patient-reported outcome measure (PROM) specifically designed to evaluate the physical function of individuals who have undergone limb-salvage surgery for bone or soft-tissue sarcomas.The raw score is converted into a percentage ranging from 0 to 100. Higher score indicates better function.
From surgery to 24 months, assessed every 3 months
Overall survival (OS)
Časové okno: From surgery to 24 months, assessed every 3 months
Overall survival is defined as the time from definitive surgery to death from any cause. Participants alive at last follow-up will be censored. Survival status will be assessed at each scheduled visit.
From surgery to 24 months, assessed every 3 months
Need for re-biopsy
Časové okno: preoperative period
Number of participants requiring more than one biopsy procedure to obtain a definitive diagnostic result.
preoperative period
Request for external pathology consultation
Časové okno: perioperative period
Number of participants for whom a second opinion from an external pathology department was sought to confirm the primary diagnosis.
perioperative period
intraoperative blood loss
Časové okno: During the surgical procedure
Total volume of blood lost during the surgical procedure, measured in milliliters (mL).
During the surgical procedure
length of hospital stay
Časové okno: perioperative period
The total number of days from the date of admission to the date of hospital discharge. This is a continuous outcome
perioperative period
Major wound complications
Časové okno: Assessed from the date of surgery to 120 days after surgery.

Major wound complication was defined according to the O' sullivian et al (the Lancet, 2002). They are defined as a secondary operation under general or regional anaesthesia for wound repair (debridement, operative drainage, and secondary wound closure including rotationplasty, free flaps, or skin grafts),or wound management without secondary operation.

Wound management included an invasive procedure without general or regional anaesthesia (mainly aspiration of seroma), readmission for wound care such as intravenous antibiotics, or persistent deep packing for 120 days or longer. It will be recorded as binary outcome

Assessed from the date of surgery to 120 days after surgery.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. května 2026

Primární dokončení (Odhadovaný)

1. prosince 2031

Dokončení studie (Odhadovaný)

1. prosince 2033

Termíny zápisu do studia

První předloženo

2. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

4. května 2026

První zveřejněno (Aktuální)

8. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

8. května 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

4. května 2026

Naposledy ověřeno

1. listopadu 2025

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • LN_Biopsy_2025

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na biopsy tract resection

Předplatit